Document is current

Any future updates will be listed below

Publisher Correction: Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma

Crossref DOI link: https://doi.org/10.1038/s41591-018-0235-z

Published Online: 2018-10-05

Published Print: 2018-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark